An observational study in Breast Cancer, sponsored by National Cancer Center, Korea. Enrolling by invitation at 1 site in South Korea. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-12-22.
Sponsored by National Cancer Center, Korea · Observational
breast cancer occurred 19,219cases in 2015 and is the second most common cancer among female cancers in the country. despite there's been a disease understanding and treatment developing through study, the prevalence and mortality of breast cancer have increased steadily over the last 15 years. In the last 20 years, through random clinical studies of breast cancer, radiation therapy is well-established standard therapy as postoperative supplement of invasive breast cancer and intraepithelial carcinoma but, the need for further study with new questions about radiation therapy has been raised through these studies. according to the prospective study outcome, the radiation treatment of the regional lymph node in breast cancer patients with lymph node positive increases the free-disease survival rate, radiation therapy for regional lymph node is being actively treated than in the past. on the contrary, the results of another study are being reported that treating regional lymph node may increase the risk of arm edema, radiation pneumonia and heart toxicity. In the recently, due to advancement in radiation therapy technique, the implement of new radiation therapy such as IMRT that reducing radiation dose to normal tissues of the axillary, lungs, heart and others has been actively attempted.
additional research is needed on dose-fractionation schedule, regional lymph node treatment, post-treatment toxicity of radiation therapy in breast cancer. this study establishes a prospective cohort at breast cancer patients with radiation treatment and analyze the local and regional lymph node control, recurrence, toxicity, radiation planning, clinical data, discover the factors that predict local control, regional control, overall survival, recurrence-free survival, toxicity for treatment, so we intend to construct basic data that establishes a radiation treatment strategy based on comprehensive outcomes and predictors.
12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 184 across 2,711 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →National Cancer Center, Korea is the lead sponsor of 203 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
breast cancer patient
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- disagreed to participate in the study
local and regional lymphnode control, free-recurrence, survival period
local and regional lymphnode control, free-recurrence, survival period is defined as the date of occurrence or end based of an event on the date of breast cancer diagnosis. the date of occurrence of an event means the progress of local and region lymph node by disease, the recurrence(or progression) of disease or the confirmed date of death and the date of disconnection means the final date on which the event was determined not to have occurred. * In follow up loss, the date on which survival is confirmed before follow up loss is disconnection date. * a cancer diagnosis date is calculated based on the date of radiological examination of the findings.
Time frame: up to 6 month
therapeutic responses according to image examination
therapeutic responses according to image examination is calculated as the fraction of the subjects who showed either 'CR' or 'PR' according to the RECIST criteria. \*Response Criteria (RECIST) * \[Complete Response (CR)\]: disappearance of all extranodal target lesion. * \[Partial Response (PR)\]: At least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters * \[Stable Disease (SD)\]: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD * \[Progressive Disease (PD)\]: SLD increased by at least 20% from the smallest value on study or a new tumor has been created.
Time frame: up to 6 month
toxicity of radiotherapy
toxicity is calculated as the fraction of toxicity higher than grade 3 according to CTCAE.
Time frame: up to 6 month
Started Jul 2019 (actual). Primary completion is estimated for Jun 2022, 34 months after the start.
Of 1,012 non-industry observational studies under Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 141. This study's planned 34 months is below that.
Counting every sponsor, half of 1,165 studies reached it within 58 months; a quarter within 26 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Center, Korea →